Proprietary non-aqueous formulation technology designed to enable room-temperature stable, ready-to-use injectable formulations of peptide and small molecule drugs; used in Gvoke commercially and in clinical trials for XP-8121; available for partnership licensing across therapeutic areas

XeriJect

Proprietary non-aqueous viscoelastic pharmaceutical suspension technology enabling small-volume subcutaneous injections of large molecules including proteins, monoclonal antibodies, and vaccines; available for partnership licensing across therapeutic areas

Biotech Distilled coverage (1)

2026-07-23 Xeris Biopharma (XERS) — Scientific Deep Dive for Recorlev, XP-8121, and the XeriSol/XeriJect Platform

Articles open on Substack. Some deep dives are subscriber-only.